Skip to main content

RETRACTION article

Front. Microbiol., 01 December 2023
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fmicb.2023.1334746

Retraction: vB-ApyS-JF1, the first Trueperella pyogenes phage, shows potential as an alternative treatment strategy for Trueperella pyogenes infections

This article is a retraction of:

  1. RETRACTED: vB-ApyS-JF1, the First Trueperella pyogenes Phage, Shows Potential as an Alternative Treatment Strategy for Trueperella pyogenes Infections

    1. Read original article
\r\nFrontiers Editorial Office Frontiers Editorial Office*

A Retraction of the Original Research Article
vB-ApyS-JF1, the first Trueperella pyogenes phage, shows potential as an alternative treatment strategy for Trueperella pyogenes infections

by Ji, Y., Song, L., Zhou, Z., Liu, X., Li, F., Guo, Z., Guan, Y., Yang, L., Feng, X., Sun, C., Lei, L., Han, W., and Gu, J. (2021). Front. Microbiol. 12:736304. doi: 10.3389/fmicb.2021.736304

Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating that further analysis of phage vB-ApyS-JF1 sequencing data discovered contamination with Mammaliicoccus sciuri DNA instead of Trueperella pyogenes. The conclusions reported in the article are no longer supported by the analyses; therefore, the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers of Microbiology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

Citation: Frontiers Editorial Office (2023) Retraction: vB-ApyS-JF1, the first Trueperella pyogenes phage, shows potential as an alternative treatment strategy for Trueperella pyogenes infections. Front. Microbiol. 14:1334746. doi: 10.3389/fmicb.2023.1334746

Received: 07 November 2023; Accepted: 29 November 2023;
Published: 01 December 2023.

Approved by:

Rustam Aminov, University of Aberdeen, United Kingdom

Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.